Can a pill reverse eye bulging in thyroid eye disease?

NCT ID NCT07753603

First seen Aug 07, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This clinical trial tests whether an oral medication called linsitinib can reduce eye bulging (proptosis) in people with moderate to severe active thyroid eye disease (TED). Participants will take either linsitinib or a placebo twice daily for 24 weeks. The main goal is to see if more people taking linsitinib achieve a meaningful reduction in eye bulging compared to those on placebo. The study also monitors safety and other effects on eye symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
linsitinib
What this could lead to
If successful, linsitinib could become a new oral treatment to reduce eye bulging and improve quality of life for people with thyroid eye disease.
What could go wrong
This is a phase 3 trial, but results are not guaranteed. The drug may not outperform placebo, and side effects are possible. The study is relatively small (130 participants), which may limit generalizability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAVES ORBITOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Advancing Research International

    RECRUITING

    Las Vegas, Nevada, 89144, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.